

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	DigitalX Limited
ABN	59 009 575 035

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter Irwin Rubinstein
Date of last notice	15 September 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	RIP Opportunities Pty Ltd ATF PIR Super Fund. Peter Irwin Rubinstein is the sole director and shareholder of RIP Opportunities Pty Ltd and sole member of PIR Super Fund. Irwin Biotech Nominees Pty Ltd ATF BIOA Trust. Peter Irwin Rubinstein is the sole director and shareholder of Irwin Biotech Nominees Pty Ltd and a beneficiary of BIOA Trust. ValueAdmin.Com Pty Ltd. Peter Irwin Rubinstein is the sole director and shareholder
Date of change	14 November 2017 - 21 November 2017

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>Direct</p> <p>617,284 Subscription Options exercisable at \$0.0324 each on or before 1 September 2020</p> <p>Indirect</p> <p>17 Convertible Notes with a face value of \$10,000 each, converting to fully paid ordinary Shares at \$0.027 per Share (6,296,296 Shares) and maturing on 14 September 2018¹</p> <p>1,700,000 Convertible Note Options exercisable at \$0.0324 each on or before 14 September 2019¹</p> <p>8,000,000 Broker Performance Options exercisable at \$0.0324 each on or before 14 September 2019¹</p> <p>10 Convertible Notes with a face value of \$10,000 each, converting to fully paid ordinary Shares at \$0.027 per Share (3,703,704 Shares) and maturing on 14 September 2018²</p> <p>1,000,000 Convertible Note Options exercisable at \$0.0324 each on or before 14 September 2019²</p> <p>7,000,000 Broker Performance Options exercisable at \$0.0324 each on or before 14 September 2019³</p> <p>1. Held by Irwin Biotech Nominees Pty Ltd ATF BIOA Trust. 2. Held by RIP Opportunities Pty Ltd ATF PIR Super Fund. 3. Held by ValueAdmin.Com Pty Ltd.</p>
<p>Class</p>	<p>Fully Paid Ordinary Shares</p> <p>Incentive Options exercisable at \$0.0324 on or before 14 November 2019</p> <p>Broker Performance Options exercisable at \$0.0324 each on or before 14 September 2019</p> <p>Convertible Notes with a face value of \$10,000, converting to Fully Paid Ordinary Shares at \$0.027 per Share and maturing 14 September 2018</p>
<p>Number acquired</p>	<p>14,703,704 Fully Paid Ordinary Shares</p> <p>2,000,000 Incentive Options exercisable at \$0.0324 on or before 14 November 2019</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Number disposed</p>	<p>4,724,697 Fully Paid Ordinary Shares</p> <p>10 Convertible Notes with a face value of \$10,000, converting to Fully Paid Ordinary Shares at \$0.027 per Share and maturing 14 September 2018</p> <p>11,000,000 Broker Performance Options exercisable at \$0.0324 each on or before 14 September 2019</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>4,724,697 Shares at an average price \$0.2021 per Share</p> <p>11,000,000 Shares at \$0.0324 per Share</p> <p>3,703,704 Shares at \$0.027 per Share</p> <p>2,000,000 Incentive Options issued for nil consideration</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held after change</p>	<p>Direct</p> <p>617,284 Subscription Options exercisable at \$0.0324 each on or before 1 September 2020</p> <p>Indirect</p> <p>5,000,000 Fully Paid Ordinary Shares¹</p> <p>979,007 Fully Paid Ordinary Shares²</p> <p>4,000,000 Fully Paid Ordinary Shares³</p> <p>17 Convertible Notes with a face value of \$10,000 each, converting to fully paid ordinary Shares at \$0.027 per Share (6,296,296 Shares) and maturing on 14 September 2018¹</p> <p>1,700,000 Convertible Note Options exercisable at \$0.0324 each on or before 14 September 2019¹</p> <p>1,000,000 Broker Performance Options exercisable at \$0.0324 each on or before 14 September 2019¹</p> <p>1,000,000 Convertible Note Options exercisable at \$0.0324 each on or before 14 September 2019²</p> <p>3,000,000 Broker Performance Options exercisable at \$0.0324 each on or before 14 September 2019³</p> <p>2,000,000 Incentive Options exercisable at \$0.0324 on or before 14 November 2019</p> <p>1. Held by Irwin Biotech Nominees Pty Ltd ATF BIOA Trust.</p> <p>2. Held by RIP Opportunities Pty Ltd ATF PIR Super Fund.</p> <p>3. Held by ValueAdmin.Com Pty Ltd.</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>11,000,000 Fully Paid Shares issued on Conversion of 11,000,000 Broker Performance Options exercisable at \$0.0324 expiring 14 September 2019</p> <p>4,724,697 Fully Paid Shares sold via on market trade.</p> <p>3,703,704 Shares Issued on Conversion of 10 Convertible Notes with a face value of \$10,000, converting to Fully Paid Ordinary Shares at \$0.027 per Share and maturing 14 September 2018 (with 2,000,000 free attaching Incentive Options)</p>

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.